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Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is involved in multiple brain functions. To clarify the cause of
abnormal behavior in PACAP deficient-mice, we attempted the identification of genes whose expression was altered in the
dentate gyrus of PACAP-deficient mice using the differential display method. Expression of stathmin1 was up-regulated in
the dentate gyrus at both the mRNA and protein levels. PACAP stimulation inhibited stathmin1 expression in PC12 cells,
while increased stathmin1expression in neurons of the subgranular zone and in primary cultured hippocampal neurons
induced abnormal arborization of axons. We also investigated the pathways involved in PACAP deficiency. Ascl1 binds to
E10 box of the stathmin1 promoter and increases stathmin1 expression. Inhibitory bHLH proteins (Hes1 and Id3) were
rapidly up-regulated by PACAP stimulation, and Hes1 could suppress Ascl1 expression and Id3 could inhibit Ascl1 signaling.
We also detected an increase of stathmin1 expression in the brains of schizophrenic patients. These results suggest that up-
regulation of stathmin1 in the dentate gyrus, secondary to PACAP deficiency, may create abnormal neuronal circuits that
cause abnormal behavior.
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Introduction
PACAP is a neuropeptide that is expressed in the brain as well
as in the neurons of a number of peripheral organs and it is
involved in various neurobiological functions, such as neurotrans-
mission and neural plasticity [1,2]. It also has a neurotrophic effect
via three heptahelical G protein-coupled receptors, one of which is
specific for PACAP (PAC1 receptor) and two others that are
shared with vasoactive intestinal polypeptide (VPAC1 and VPAC2
receptors) [3]. Recently, mice that lack Adcyap1, the gene encoding
PACAP, (Adcyap1
2/2 mice) were developed [2,4]. Adcyap1
2/2
mice display remarkable behavioral abnormalities providing
evidence that PACAP plays a previously uncharacterized role in
the regulation of psychomotor behavior. When placed into a novel
environment, such as an open field, the mutants display
significantly increased locomotor activity with minimal time spent
habituating themselves to the environment, and less time engaged
in licking and grooming behavior. The mutants also show
explosive jumping behavior in the open field and increased
exploratory behavior [2,5]. These behavioral abnormalities may
be due to perturbation of monoamine neurotransmission because
serotonin metabolite 5-hydroxyindoleacetic acid is slightly de-
creased in the cerebral cortex and striatum of PACAP-deficient
mice, and hyperactive behavior is ameliorated by the antipsychotic
drug, haloperidol [2]. In addition, the jumping behavior is
suppressed by drugs that elevate extracellular serotonin, such as
the selective serotonin reuptake inhibitors [6]. Adcyap1
2/2 mice
also showed increased immobility in a forced swimming test,
which was reduced by the antidepressant, desipramine [7]. In
addition it is known that PAC1-deficient mice exhibit reduced
social behavior [8]. And, it is also known that PAC1-deficient mice
exhibit increased fear conditioning and a reduction of LTP [9]. A
previous association study reported that several single nucleotide
polymorphisms (SNPs) in the vicinity of the PACAP gene locus
were associated with schizophrenia [10]. However, none of
genome wide association studies showed association of this gene
with schizophrenia [11]. Disrupted-In-Schizophrenia 1 (DISC1) has
been identified as a potential susceptibility gene for major
psychiatric disorders [12,13]. We previously identified several
DISC1-interacting factors [14,15,16]. DISC1-binding zinc finger
protein (DBZ) is one of these factors. We found that PACAP up-
regulates DISC1 expression and markedly reduced the association
of DISC1 with DBZ in PC12 cells, and that a DISC1-binding
domain of DBZ reduces neurite length in PC12 cells following
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[12]. Therefore, these results suggest that PACAP may play a role
in mental disorders such as schizophrenia.
However, nothing is known about the mechanisms of PACAP
deficiency-induced psychiatric illness, so this study was performed
to investigate these mechanisms.
The localization of PAC1 mRNA in the neurons of rat and mice
brains has been examined by in situ hybridization [17]. Neurons
showing intense signals for PAC1 mRNA were found in the
dentate gyrus of the hippocampus, olfactory bulb, second layer of
the cerebral cortex, and several hypothalamic areas. In addition,
an atrophy of the hippocampus had been reported in schizo-
phrenic patients [10]. To elucidate molecular events associated
with PACAP deficiency in the mouse brain that could be relevant
to schizophrenia, therefore we attempted to detect PACAP
deficiency-regulated genes in the dentate gyrus using the
differential display (DD) method and found that stathmin1
expression was up-regulated in the dentate gyrus of PACAP-
deficient mice. Stathmin1 is expressed at high levels by neurons
and glial cells of the brain [18,19]. It interacts with tubulin and
destabilizes microtubules [20]. However, the detailed functions
and regulatory mechanisms of stathmin1 in the formation of
neural networks are unclear.
In this study, we found that an increase of stathmin1 expression
induced abnormal sprouting of neurons in the dentate gyrus, and
we showed that stathmin1 was regulated by a basic helix loop helix
(bHLH) factor via a PACAP-dependent molecular signaling
pathway.
Methods
Animals
Adcyap
2/2 mice and wild-type littermates were provided by the
Baba lab, Laboratory of Molecular Neuropharmacology, Gradu-
ate School of Pharmaceutical Sciences, Osaka University.
Pregnant female rats were deeply anesthetized with sodium
pentobarbital. Brains were dissected from day 18 embryos and
cultured. All animal experiments were carried out in accordance
with a protocol approved by the Institutional Animal Care and
Use Committee of Osaka University.
Construction of the stathmin1, Ascl1, Hes1 and Id3
expression vectors
Mouse stathmin1 cDNA was subcloned into pEGFP-C3
(Clontech) to generate stathmin1 with green fluorescent protein
(GFP) fused to the N-terminal (GFP-stathmin1) and into a
bicistronic expression vector (pIRES2-EGFP; Clontech) to pro-
duce stathmin1–IRES–GFP. A mouse Hes1 expression plasmid,
pCI-Hes1, and Hes1 antibody were kind gifts from Prof. R.
Kageyama. Rat Ascl1 and Id3 were sub-cloned into pCI-neo
(Clontech).
Cell culture and transfection
PC12 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% horse serum and 5% FBS in
a5 %C O 2/95% air humidified atmosphere at 37uC. Twenty four
hours after plating, PACAP was applied. The inhibitors were
added 1 h before PACAP treatment. Rat primary hippocampal
neurons were prepared from day 18 embryos using nerve cell
culture system MB-X9901 (Sumitomo Bakelite, Tokyo, Japan) as
described in the Sumilon Protocol N-4.2. Neurons were plated on
poly-L-lysine coated chamber slides and cultured in MEM with
5% FCS in a 5% CO2/95% air humidified atmosphere at 37uC.
Approximately 1610
5 neurons or 6610
5 PC12 cells were
transfected with 2 mgo r1mg of pGFP-Stathmin1, pStathmin1–
IRES–GFP or a GFP only expression vector using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA).
Construction of rat stathmin1 promoter-luciferase
plasmids
Rat stathmin1 genomic sequence (PubMed accession
no. NC_005104) was identified using a BLAST search with
stathmin1 cDNA sequence, and a 1.9 kb region corresponding
21534 to +325 was amplified by PCR using forward primer 59-
and reverse primer 59- containing KpnI and NheI sites and
subcloned into the KpnI-NheI site of the pGL3 basic vector. This
plasmid is designated as STMN1-1. Deletion constructs, STMN1-
2( 21343/+325), STMN1-3 (21264/+325) and STMN1-4
(21152/+325) were produced by fill-in reaction with DNA
polymerase (Klenow fragment) and blunt end ligation.
Transient transfection and luciferase assays
Transient transfections with various promoter constructs were
performed using Lipofectamine (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Cells in 6-well dishes
were transfected with either 0.1 mg of empty pGL3vector or with
promoter-reporter constructs (STMN1-1, STMN1-2, STMN1-3
and STMN1-4), along with 1 ng Renilla luciferase plasmid pRL.
In co-transfection experiments, different amounts of Ascl1, Id3
and Hes1 expression plasmids were added. The total amount of
DNA added in each transfection was kept constant by addition of
an empty control vector. 48 h after transfection, cells were washed
with pre-chilled PBS and lysed in passive lysis buffer (Dual
Luciferase kit, Promega). Firefly luciferase and Renilla luciferase
activities in the cell lysates were measured according to the
manufacturer’s instructions using a TD 20/20-luminometer
(Turner Biosystems, Sunnyvale, CA, USA). Firefly luciferase
activity was normalized to the Renilla luciferase activity and
reported as relative luciferase activity (RLA).
Preparation of RNA and Real-Time RT-PCR
The hippocampus was rapidly dissected from each brain, and
the hippocampus was divided into Ammon’s horn and the dentate
gyrus [21]. Preparations of total RNA from the tissues were
performed as previously described [22]. Total RNA was isolated
from PC12 cells using the RNA Easy Kit (Qiagen, Tokyo, Japan).
Each RNA was transcribed to cDNA using reverse transcription
reagents (Superscript III; Invitrogen or High-Capacity cDNA
Reverse Transcription Kit; Applied Biosystems) according to the
manufacturer’s instructions.
Real-time RT-PCR was performed on a thermocycler (7900HT
Sequence Detection Systems; Applied Biosystems, Foster, CA, USA)
with nuclear stain reagents (SYBR Green; Applied Biosystems),
according to the manufacturer’s instructions. Amplification of PCR
products was measured by fluorescence associated with the binding of
double-stranded DNA to the SYBR green dye in the reaction
mixture. Quantification of each PCR product was expressed relative
to GAPDH. The following primers were used: mouse stathmin1;
forward, 59-ccaggcttttgagctgattc; reverse, 59-gcgtctttcttctgcagctt,
mouse GAPDH; forward, 59-attgtggaagggctcatgacc; reverse, 59-atgc-
agggatgatgttctggg, rat stathmin1; forward, 59-aatggcagaggagaaact-
gacc; reverse, 59-cgtgcttgtccttctctcgc, rat Id3; forward, 59-acatgaac-
cactgctactcgcg; reverse, 59-cagaaccacttgaaggtcgagg, rat Hes1; for-
ward, 59-aaatgacagtgaagcacctccg; reverse, 59-ttaacgccctcacacgtgg, rat
Ascl1;forward,59- ttaacctgggctttgccac; reverse, 59- agcgcgcggatgtattc,
rat GAPDH; forward, 59- gccttctcttgtgacaaagtgg; reverse, 59-
attctcagccttgactgtgcc.
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ChIP assays were performed using a ChIP kit (Millipore TM)
following the manufacturer’s protocol. Briefly, PC12 cells were
cross-linked, chromatin was prepared and immunoprecipitated
with anti-Ascl1 antibody (Santa Cruz) or with control IgG. Then,
immunoprecipitated DNA was eluted and PCR amplified using
appropriate primers. For PCR amplification of the E10–11 box
(40 cycles), the E10 box (50 cycles) and the negative control (N.C.)
(55 cycles), the following primers were used: E10–E11-forward, 59-
tgcctctataagcatattttacgc; E10–E11-reverse, 59-atttggtctcccaaaagc-
taaacc; E10-forward, 59-cagttttcattgtcttgtatgcctg; E10-reverse, 59-
atttggtctcccaaaagctaaacc; N.C.-forward, 59-gctccgatctcattgttgg;
N.C.-reverse, 59-tcatctagaaacaccgaagcc.
Immunoblot analysis
Lysates of PC12 cells and of hippocampal dentate gyrus were
used directly for western blot analysis as described previously
[14,21]. The following antibodies were employed: rabbit poly-
clonal anti-stathmin1 (GeneTex). Goat anti-rabbit or anti-mouse
IgG conjugated with horseradish peroxidase (Cell Signaling
Technology, Beverly, MA, USA) were used as the secondary
antibodies. Reaction products were visualized by detection of
chemiluminescence using an ECL kit (Amersham Biosciences,
Piscataway, NJ, USA). Quantitation of relative band densities was
performed by scanning densitometry. All experiments were
repeated independently at least three times. PC12 cells were
cultured for 1 day at a low cell density, starved of serum for 4 h,
and then treated with 100 nM PACAP (PACAP-38) (Peptide
Institute, Mino, Osaka, Japan). Cells were harvested at the
indicated times after PACAP stimulation.
Immunohistochemistry
Sections (20 mm) were prepared from frozen brains using a
cryostat and thaw-mounted on APS coated slides (Matsunami,
Japan) and stored in a tightly closed case at 280uC. The following
antibodies were employed: rabbit polyclonal anti-stathmin1
(GeneTex), mouse monoclonal anti-MAP2 (Sigma), anti-Tau
(Sigma), and anti-Asc11 (Santa Cruz Biotechnology). Floating
sections were incubated with these antibodies overnight at 4uC.
Confocal microscopy was performed using an LSM-510 laser
scanning microscope (Carl Zeiss, Oberkochen, Germany).
Quantification of stathmin1 positive cells in the
subgranular zone (SGZ) and of dot fibers in the hilus
Stathmin1 cells were counted in coronal sections. The entire
DG region of each hippocampus was imaged as a z-series of
20 mm-thick sections. All data analysis was blind to genotype.
Statistical analysis was performed using Student’s t-test.
After immunolabeling for stathmin1 in equivalent coronal
sections, a 20 mm-thick z-series of confocal images was collected in
dentate gyrus of hippocampus.
Double labeling with in situ hybridization and
immunohistochemistry
The protocol for the in situ hybridization (ISH) histochemistry
was modified from a previously published method [23]. cDNA
fragments of rat PAC1 were amplified by RT-PCR using the
oligonucleotide primers 59-cttgtacagaagctgcagtc-39 (sense) and
59-ggtgcttgaagtccatagtg-39 (antisense) and then used as tem-
plates for probe synthesis. For double ISH and immunohisto-
chemistry, sections were immunostained followed by ISH. The
protocol for immunohistochemistry was based on the published
ABC method (Elite ABC kit; Vector, CA, USA) using the rabbit
anti-stathmin1 primary antibody at 1:500. The specificity of the
immunohistochemistry was checked by omitting the primary
antibody.
Immunoelectron microscopy
Eight week-old mice were deeply anesthetized with sodium
pentobarbital and perfused transcardially with 0.85% physiolog-
ical saline followed by 0.05% glutaraldehyde and 4% paraformal-
dehyde in a 0.1 M phosphate buffer (pH 7.4). Brains were
removed and post-fixed in the same fixative for 4 h at 4uC,
followed by immersion in 30% sucrose in 0.1 M PB overnight at
4uC. 20 mm brains sections were then cut on a cryostat.
Immunohistochemistry was performed using free-floating sections
according to the ABC method. The anti-stathmin antibodies were
used at a dilution of 1:1000. Biotinylated anti-rabbit IgG
(Vectastain Elite) was used as a secondary antibody. Immunore-
activity was visualized with 0.05% diaminobenzidine and 0.01%
hydrogen peroxide in 50 mM Tris, pH 7.6. These sections were
washed several times in a 0.1 M phosphate buffer (pH 7.4) and
after post-fixation with 1% OSO4 for 1 h and dehydration they
were flat-embedded in Epon 812. Ultrathin sections were viewed
without uranyl acetate or lead citrate staining using an H-7000
electron microscope (Hitachi).
Quantitative RT-PCR assays using Postmortem Brain
samples
RNA samples from the dorsolateral prefrontal cortex (DLPFC;
Brodmann’s area 46) were obtained from the Stanley Medical
Research Institute (http://www.stanleyresearch.org/programs/
brain_collection.asp). Samples were taken from 35 schizophrenics (26
males, 9 females; mean6SD age, 42.668.5 years; postmortem interval
(PMI), 31.461 5 . 5h ;b r a i np H ,6 . 5 60.2), 35 bipolar disorder patients
(17 males, 18 females; mean6SD age, 45.3610.5 years; PMI,
37.9618.3 h; brain pH, 6.460.3), and 35 controls (26 males, 9
females; mean6SD age, 44.267.6 years; PMI, 29.4612.9 h; brain
pH, 6.660.3). Diagnoses were made by applying DSM-IV (the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)
criteria.Allschizophrenicpatientsweremedicatedwithanti-psychotics.
Quantitative RT-PCR analysis was conducted using an ABI7900HT
Fast Real-Time PCR System (Applied Biosystems) with TaqMan
Gene Expression Assays (Applied Biosystems). All quantitative RT-
PCR reactions were performed in triplicate, based on a standard curve
method. Detection values are normalized according to the internal
controls (GAPDH, ACTB and PGK1). TaqMan probes for STMN1,
GAPDH,ACTB,and PGK1 were selected from predesigned TaqMan
Gene Expression Assays (AssayID: STMN1, Hs01027516_g1;
GAPDH, Hs99999905_m1; ACTB, Hs99999903_m1; PGK,
Hs99999906_m1). The Mann-Whitney U test (two–tailed) was used
to detect significant changes in target gene expression levels.
Association Study Subjects
The case-control samples consisted of 1060 unrelated schizo-
phrenic patients (503 men, 557 women; mean age 48.0613.8
years) and 1060 age- and sex-matched controls (503 men, 557
women; mean age 47.7613.6 years). All patients had a consensual
diagnosis of schizophrenia according to DSM-IV criteria from at
least two experienced psychiatrists. Control subjects were recruited
from hospital staff and volunteers who showed no present or past
evidence of psychoses, during brief interviews by psychiatrists. All
participants were recruited from a geographic area located in
central Japan. The current study was approved by the Ethics
Committees of RIKEN. All participants provided written
informed consent.
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Three SNPs, rs159522, rs12037513 and rs807061 located in
close vicinity of the STMN1 gene were genotyped in this study.
SNP genotyping was performed using the TaqMan system
(Applied Biosystems, Foster City, CA, USA) according to the
recommendations of the manufacturer. PCR was performed using
an ABI 9700 thermocycler. Fluorescent signals were analyzed
using an ABI7900HT Fast Real-Time PCR System and SDS v2.3
software (Applied Biosystems).
Statistical Analyses
Concerning the association study, analysis of the significance of
differences in mRNA expression between the control group and
the chronic stress group was performed using Student’s t-test. The
allelic and genotypic distributions in the Japanese case-control
samples were tested for association by Fisher’s exact test.
Haplotypic association analysis of Japanese samples was per-
formed using the COCAPHASE program in the UNPHASED
v3.0.11 program (http://www.mrc-bsu.cam.ac.uk/personal/
frank/software/unphased/) [Dudbridge, 2008]. To estimate the
degree of linkage disequilibrium (LD), the standardized disequi-
librium coefficient (D9) and the squared correlation coefficient (r2)
were calculated using Haploview 4.0 (http://www.broad.mit.edu/
mpg/haploview/). The deviation of genotype distributions from
the Hardy–Weinberg equilibrium (HWE) was evaluated by the
chi-squared test (d.f.=1). Other results were expressed as the
mean6SE, with statistical analysis being performed by a one way
ANOVA.
Results
Down-regulation of PACAP expression induces up-
regulation of stathmin1 expression in the dentate gyrus
both in vivo and in vitro
To detect the genes regulated by PACAP, we searched for gene
transcripts that were clearly up-regulated or down-regulated in the
dentate gyrus of Adcyap
2/2 mice.
The differential display (DD) method showed that 55 cDNA
fragments were up-regulated or down-regulated in the dentate
gyrus of Adcyap
2/2 mice compared with wild-type mice. One of
these genes, stathmin1, was subjected to further analysis. Real-
time PCR showed that stathmin1 mRNA was markedly increased
in the dentate gyrus of Adcyap
2/2 mice (Fig. 1A). Increased
stathmin1 protein levels in the dentate gyrus of Adcyap
2/2 mice
were also confirmed by western blot analysis (Fig. 1B). Thus,
PACAP deficiency induced elevation of stathmin1 in the dentate
gyrus.
We then examined whether the in vivo changes described above
could be reproduced in vitro using PC12 cells. Stathmin1 mRNA
levels were decreased 3 hours after PACAP stimulation, and
expression continued to decrease over the next 24 hours (Fig. 1C).
PACAP stimulation of PC12 cells caused stathmin1 protein levels
to decrease (Fig. 1D), and also caused a dose-dependent decrease
of stathmin1 mRNA levels (Fig. 2A). The decrease of stathmin1
expression by PACAP stimulation was slightly, but statistical
significantly, inhibited by pretreatment with a PAC1/VPAC2
receptor antagonist (PACAP6-38) (Fig. 2B). We did not perform
the Western blot analysis, because we assumed that this small
difference would not be detectable due to the limitation of its
sensitivity. Pretreatment with a p38 antagonist (SB202190) or an
ERK antagonist (PD98059) also inhibited the decrease of
stathmin1 expression by PACAP (Fig. 2C). Co-administration of
SB202190 and PD98059 strongly inhibited the effect of PACAP
(Fig. 2C). The p38 and ERK are key elements of the PACAP
signaling pathway (supplementary Fig. S1). On the other hand,
VIP did not decrease stathmin1 expression (Fig. 2D). These results
indicate that PACAP inhibits stathmin1 expression in PC12 cells.
Furthermore, we showed that PACAP regulates stathmin1
expression via the PAC1 receptor in neurons of the dentate gyrus
subgranular zone, as described below.
Up-regulation of stathmin1 induces abnormal axonal
arborization in neurons of the dentate gyrus subgranular
zone
Stathmin1 is mainly localized in subgranular zone
neurons with prominent localization in cell proce-
sses. Immunohistochemistry for stathmin1 in the dentate gyrus
of wild-type mice showed that cells expressing stathmin1 were
preferentially localized in the innermost part of the granular cell
layer, the so-called subgranular zone (SGZ) where neurogenesis of
granular cells occursin adults (Fig. 3A, B). A large number of cells in
the SGZ expressed stathmin1. Immunohistochemical analysis also
Figure 1. Stathmin1 expression is negatively controlled by
PACAP. (A, B) Comparison of stathmin1 expression of wild-type mice
to that of Adcyap
2/2 mice. (A) Expression level of stathmin1 mRNA in
DG was measured by real-time RT-PCR and normalized to the
expression of GAPDH. Data represents means6SEM of independent
experiments (wild type n=10, Adcyap
2/2 n=10, ***P=0.0000496
compared with wild type). (B) Expression of stathmin1 protein in the
DG of wild type and Adcyap
2/2 mice measured by western blot analysis
(upper panel). GAPDH was used as internal control (middle panel).
Lower panel shows the ratio of stathmin1 protein level in DG of
Adcyap
2/2 mice (closed column) to that of wild-type mice (open
column). Error bars represent 6SEM. (wild-type n=4, Adcyap
2/2 n=4,
**P=0.00277 compared with wild-type). (C, D) Kinetic studies of the
effect of PACAP signaling on stahmin1 expression levels in PC12 cells.
(C) Alteration of stathmin1 mRNA levels by the indicated period of
PACAP (100 nM) stimulation was quantified by real-time PCR. Data are
expressed as mean percentages 6SEM relative to control values at 0 h.
Open circle indicates vehicle treatment. Closed circle represents PACAP
treatment. (D) Alteration of stathmin1 protein levels under the
indicated period of PACAP (100 nM) stimulation was measured by
western blot analysis using an anti-stathmin1 antibody.
doi:10.1371/journal.pone.0008596.g001
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processes; thick processes and dot-like processes. Thick processes
in the granular cell layer could often be traced to the soma of
stathmin1-positive cells (Fig. 3A, B). Numerous dot-like processes
were exclusively found in the polymorphic layer and often formed
varicosities (Fig. 4A, B white arrows). Immunoelectron microscopy
established that stathmin1 positive cells extend neurites to the hilus,
and that these neurites were axons, judging by their morphology
(Fig. 3D, E). Thus, the dot-like processes were the fragments of
axons (Fig. 3F), while the thick processes to the granular cell layer
were dendrites (Fig. 3G). Similarly, primary cultured neurons
expressed stathmin1 in the soma and processes under normal
conditions. MAP2 and Tau staining established that stathmin1 was
expressed in dendrites (Fig. 3H, I, J) and in axons (Fig. 3K, L, M).
Elevation of stathmin1 in dentate gyrus neurons causes
abnormal axonal arborization. Immunoreactivity for
stathmin1 was significantly increased in the SGZ neurons of
Adcyap
2/2 mice (Fig. 3A, B), although the actual number of
immunoreactive cells was similar in mutant and wild-type mice
(Fig. 3C). The number of dot-like immunoreactive fibers was
significantly increased in the polymorphic layer of Adcyap
2/2 mice
compared with wild-type mice (Fig. 4A–C). These findings show
that increased expression of stathmin1 in the SGZ neurons led to
pronounced arborization of the axons of SGZ neurons. Therefore,
we attempted to clarify whether this in vivo event could be
duplicated in vitro by using hippocampal primary cultured neurons.
Over-expression of stathmin1 caused dramatic changes of axon
fibers. As shown in Figure 4E and 4F, arborization of axon fibers
was markedly increased by stathmin1 over-expression compared
with that in normal primary cultured neurons (Fig. 4D). The
number of secondly neurites from axons was also increased
following over-expression of stathmin1 (Fig. 4G). Thus, it was
concluded that an increase of stathmin1 expression in SGZ
neurons leads to abnormal axonal arborization.
Molecular mechanism of stathmin1 regulation by PACAP
PACAP regulates stathmin1 expression via the PAC1
receptor in SGZ neurons. If PACAP directly regulates
stathmin1 expression in vivo, SGZ neurons should express PAC1.
In fact, strong expression of PAC1 mRNA was identified
throughout the entire granule cell layer, including the SGZ
(Fig. 5A). Figure 5C shows the localization of stathmin1-expressing
neurons (brown) and PAC1 mRNA-expressing neurons (black
grains) in the same section of the dentate gyrus. As indicated by
Figure 2. PACAP regulated stathmin1 expression via PAC1 in PC12 cells. (A) Alteration of stathmin1 mRNA levels 24 hours after PACAP
treatment, at indicated concentrations, was quantified by real-time PCR. Data are expressed as mean percentages 6SEM relative to control values
(n=3, PACAP 1 nM **P=0.0044, 10 nM **P=0.0033, 100 nM ***P=0.0003 compared with control). (B, C) Effect of PACAP signaling pathway
inhibitors on the PACAP-induced down-regulation of stathmin1 expression. (B) PC12 cells were treated with 10 nM PACAP for 6 h and incubated with
or without the indicated concentration of PAC1/VPAC2 receptor antagonist, PACAP 6-38 (n=3, PACAP6-38 5 mM **P=0.0027, 10 mM ***P=0.00045
compared with PACAP stimulation alone) and (C) pretreatment of either ERK or p38 inhibitor (n=3, PACAP stimulation alone **P=0.0012, SB202190
***P=0.0008, ##P=0.005, PD98059 *P=0.018, #P=0.0018, SB202190 & PD98059 #P=0.013, *compared with each control, #compared with
PACAP stimulation alone). Then stathmin1 expression was quantified by real-time PCR. Data are expressed as mean ratios 6SEM relative to control
values. (D) Alteration of stathmin1 mRNA levels in PC12 cells, 6 hours after PACAP or VIP treatment at the indicated concentrations, was quantified by
real-time PCR. Data are expressed as mean percentages 6SEM relative to control values (n=3, PACAP 100 nM ***P=7.08E
207 compared with
control).
doi:10.1371/journal.pone.0008596.g002
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stathmin1 protein and PAC1 mRNA (Fig. 5C). Thus, stathmin1-
expressing neurons in the SGZ also expressed PAC1.
Stathmin1 gene promoter activity is regulated by basic
helix loop helix (bHLH) proteins. Using to perform a BLAST
search, we identified the genomic sequence of rat stathmin1 in a
chromosome 5 contig. We then performed PCR amplification of a
1885 bp genomic DNA fragment that consisted of 1561 nt
upstream of the stathmin1 transcription start site (+1), exon 1,
and part of intron 1(+325). This fragment was sequenced and
Figure 3. Stathmin1 expression in the axon and dendrite. (A–B) Immunohistochemical analysis of stathmin1 in the DG.
Immunohistochemistry of stathmin1 using wild-type mice (A) and Adcyap
2/2 mice (B). The small photograph is at high magnification. Bars=50 mm.
(C) The number of stathmin1 positive cells in the SGZ in wild-type (open column) and Adcyap
2/2 mice (closed column) were counted in a set of four
coronal sections along the rostral-caudal range of each hippocampus/DG (n=3). (D–G) Immunoelectron microscopic analysis of stathmin1-expressing
processes in the SGZ of Adcyap
2/2 mice. (D, E) Stathmin1 positive neurites originating from SGZ neurons extended to the polymorphic layer (D,
bar=5 mm) and the neurites had the morphology of axon fibers (E, bar=1 mm). (F) Stathmin1 positive dot-like fibers in the polymorphic layer
identified as the axon fibers. Bar=1 mm (G) Thick processes found in the granular cell layer could often be traced to the stathmin1 positive cell soma.
Bar=5 mm (H, K) Localization of stathmin1 in the rat hippocampal primary neurons. The same cells as in (H) and (K) stained with MAP2 antibody (I) or
anti-Tau antibody (L). (J) and (M) represent the merged image of (H) with (I), and (K) with (L), respectively. Bars=50 mm.
doi:10.1371/journal.pone.0008596.g003
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analyzed this fragment for transcription factor-binding sites using
the DNAsis program. The 1.8 kbp rat stathmin1 59 genomic
sequence contained 12 (E1–E12) putative E boxes (CANNTG),
which are potential binding sites for bHLH proteins, including
neuronal transcriptional activators (Fig. 5D). To investigate the
promoter activity of stathmin1, we constructed several expression
plasmids for the luciferase reporter assay (Fig. 5D). We examined
the activity of each construct using the luciferase assay, after
transient transfection in PC12 cells. Constructs with E10 (such as
STMN1-1, STMN1-2 and STMN1-3) showed a high level of
luciferase activity compared with control cells, but constructs with
Figure 4. Stathmin1 over-expression in neurons causes abnormally pronounced arborization of axon fibers. (A, B) Immunohisto-
chemical analysis of stathmin1 in the polymorphic layer. Immunohistochemistry of stathmin1 using wild-type mice (A) and Adcyap
2/2 mice (B). White
arrows indicate varicosities. Bars=50 mm. (C) The number of stathmin1 positive dot-like fibers in the polymorphic layer were counted (n=3,
***P=3.4E
212 compared with wild-type). Error bars represent 6SEM. (D–F) Morphology of hippocampal primary neurons transfected with stathmin1.
Over-expression of GFP (D), GFP-stathmin1 (E) or stathmin1 and GFP (F). The neurons over-expressing stathmin1 have abnormally pronounced
sprouting of axon fibers. Bars=50 mm. (G) The number of secondary neurites from axons was increased by over-expression of stathmin1 (GFP; n=10,
GFP-stathmin1; n=10, ***P=2.5E
25, GFP and stathmin1; n=6, ***P=0.00022 compared with GFP). Error bars represent 6SEM.
doi:10.1371/journal.pone.0008596.g004
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not show luciferase activity (Fig. 5E). Therefore, the E10 box was
found to be a key motif that regulates stathmin1 expression
through bHLH factors.
An activating bHLH protein, Ascl1, activates the
stathmin1 promoter. Among activating bHLH proteins, we
found that Ascl1 activated the stathmin1 promoter. Namely, co-
transfection of PC12 cells with the stathmin1-promoter plasmid and
the Ascl1 expression plasmid induced a dose-dependent increase of
luciferase activity compared with transfection of the stathmin1
promoter plasmid alone (Fig. 5F). To examine whether endogenous
Ascl1 protein in PC12 cells could bind to the stathmin1 promoter
sequence, sheared chromatin was immunoprecipitated with anti-
Ascl1 antibody or with control IgG, followed by PCR amplification
of the corresponding DNA regions using stathmin1 promoter
specific primers. Analysis of amplified DNA showed that more
sequences were amplified by primers flanking the E10 box
compared with primers flanking the E10–E11 boxes (Fig. 5G). In
addition, co-localization of Ascl1 and stathmin1 in SGZ neurons
was demonstrated by immunohistochemistry (Fig. 5H, I, J). These
results established that endogenous Ascl1 protein could bind to the
stathmin1 promoter and act as a major regulator of stathmin1
promoter activity.
Inhibitory bHLH proteins, Hes1 and Id3, show increased
expression after PACAP stimulation. As mentioned above,
both PACAP and Ascl1 regulate stathmin1 expression. In
addition, inhibitory bHLH proteins (Hes family proteins and Id
family proteins) are known to inhibit the bHLH proteins. We
detected an increase of Hes1 and Id3 expression after PACAP
stimulation (Fig. 6A, B). To establish the pathway involved, we
next examined the effect of PACAP on Hes1 and Id3 expression in
vitro. Hes1 and Id3 expression increased rapidly after PACAP
stimulation, indicating that expression of bHLH inhibitors (Hes1
and Id3) was induced by PACAP stimulation. Inhibition of
elements of the PACAP signaling pathway, such as p38 and ERK,
suppresses the effect of PACAP on stathmin1 expression.
Therefore, we next examined whether the ERK or p38 pathway
regulates the induction of Hes1 and Id3 after PACAP stimulation.
As a result, the increase of Id3 mRNA levels in response to
PACAP stimulation was inhibited by a p38 inhibitor (SB202190),
but not by an ERK inhibitor (PD98059) (Fig. 6C). Induction of
Hes1 mRNA by PACAP stimulation was inhibited by an ERK
inhibitor and by a p38 inhibitor. Furthermore, co-administration
of p38 and ERK inhibitors strongly inhibited the induction of
Hes1 mRNA by PACAP stimulation (Fig. 6D). Administration of
SB202190 or PD98059 alone did not affect the expression of Hes1
or Id3 largely. These results were represented as a relative value to
inhibitor alone. These findings suggested that Hes1 expression is
regulated by both the PACAP-ERK and PACAP-p38 pathways,
whereas Id3 expression is mainly controlled by the PACAP-p38
pathway.
Hes1 and Id3 suppress stathmin1 promoter activity via
Ascl1 inhibition. To elucidate whether the stathmin1 promoter
was regulated by Hes1 or Id3, PC12 cells were co-transfected with
a stathmin1 promoter plasmid and a Hes1 expression plasmid or
Figure 5. PACAP inhibits stathmin1 by up-regulation of Ascl1
using p38 and ERK signals. (A) Localization of stathmin1 and PAC1
expressing neurons in the DG of wild-type mice. (B) Hippocampal
section stained with hematoxylin and eosin. Bars=100 mm. (C) shows
the localization of stathmin1 and PAC1 expressing neurons in the same
section (arrows). Stathmin1 is visualized by immunohistochemistry
(brown) and PAC1 mRNA by in situ hybridization (black grains).
Bars=50 mm. (D–J) Involvement of Ascl1 in the promoter activity of
stathmin1. (D) Schematic diagram of the 1.8 kb rat stathmin1 59
genomic DNA fragments for the luciferase activity assay. These vectors
posses the 59 regulatory region of stathmin1, the first exon and partial
sequence of the first intron. The different promoter constructs used in
this study are shown. The relative location (not drawn to scale) of
putative E-boxes, and the transcription start site (arrow at +1) are
shown. (E) PC12 cells were transfected in 6-well plates with the
indicated stathmin1 promoter-luciferase plasmids and the Renilla
luciferase plasmid. Firefly and Renilla luciferase activities were measured
using a Dual Luciferase Reporter Assay System (n=3). Luciferase activity
was measured and data (means6SEM) are shown as relative luciferase
activity (RLA). (F) Activation of the STMN1-1 promoter by Ascl1. STMN1-
1 plasmid and 1 mg of expression vector, which are mixed with empty
vector pCI and the indicated amounts of pCI-Ascl1, were transfected in
triplicate, with 0.2 mg. 48 h after PC12 cell transfection, the cells were
collected and the RLA was determined. Data (mean6SEM) show
representative results of least three experiments, *P=0.0165. (G)
Sheared chromatin from PC12 cells was immunoprecipitated with the
appropriate antibody (anti-Ascl1, control rat anti-IgG). Then DNA
sequences bound to precipitated proteins were isolated. Immunopre-
cipitated DNA was used as template in PCR using E10 primers, E10–E11
primers or negative control primers. (H–J) Localization of stathmin1 (H)
and Ascl1 (I) were demonstrated on the same DG section of wild-type
mice. Arrows indicate SGZ neurons containing both stathmin1 and
Ascl1. Arrow head represents a neuron expressing stathmin1 alone.
Bar=10mm.
doi:10.1371/journal.pone.0008596.g005
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8596Figure 6. Hes1 and Id3, which are regulated by PACAP, inhibit Ascl1 function. (A, B) Kinetic study of the effect of PACAP on the expression
of Id3 (A) and Hes1 (B) mRNA. PC12 cells were treated with 10 nM PACAP for the indicated times and Id3 and Hes1 expression was quantified by real-
time PCR. Data are expressed as mean percentages 6SEM relative to control values at 0 h. Open circle indicates vehicle treatment. Closed circle
represents PACAP treatment. (C, D) Up-regulation of Id3 expression was inhibited by treatment with a p38 inhibitor (SB202190) (n=3, SB202190
*P=0.0202, SB202190 & PD98059 **P=0.0032 compared with control) (C), and expression of Hes1 mRNA was inhibited by treatment with p38
(SB202190) and ERK (PD98059) inhibitors (n=3, SB202190 ***P=1.68610
25, PD98059 *** P=0.000252, SB202190 & PD98059 *** P=8.98610
25
compared with control) (D). PC12 cells were incubated with each inhibitor for 1 h, then treated or not with 10 nM PACAP for 0.5 h. Id3 and Hes1
expression were quantified by real-time PCR. Data are expressed as mean ratios 6SEM relative to control values for inhibitor alone. (E) Effect of over-
expression of Id3 or Hes1 on the promoter activity of stathmin1. PC12 cells were transfected with STMN1-1 promoter-luciferase plasmid alone or with
Id3 expression plasmid, pCI-Id3 or Hes1 expression plasmid, pCI-Hes1. Co-transfection of Id3 or Hes1 expression plasmids inhibited the activity of
STMN1-1 promoter plasmid (n=3, +pCI- Id3 P=0.0743, +pCI-Hes1 *P=0.0305 compared with +control vector). (F) Id3, but not Hes1, inhibited the
activity of STMN1-1 promoter increased by co-transfection of Ascl1 expression plasmid, pCI-Ascl1 (n=3, +pCI-neo +Ascl1 **P=0.00385, +pCI-Hes1
+Ascl1 *P=0.025 compared with +pCI-neo, +pCI- Id3 +Ascl1 # P=0.0454 compared with +pCI-neo +Ascl1). (G) The effect of PACAP on the expression
of Ascl1 mRNA in PC12 cells. Ascl1 expression was quantified by real-time PCR (n=3, *P=0.048 compared with control). Data are expressed as mean
percentages 6SEM relative to control. (H, I) Effects of down-regulation of Hes1 on the expression level of Ascl1 mRNA. The effect of siRNAs for Hes1
are shown in (H) (n=3, siRNA1 *P=0.0159, siRNA2 **P=0.00636 compared with control). The expression level of Ascl1 was quantified by real-time
PCR (n=3, siRNA1 P=0.076, siRNA2 *P=0.0162 compared with control). Data are expressed as mean ratio 6SEM relative to control values.
doi:10.1371/journal.pone.0008596.g006
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plasmid. Even without exogenous Ascl1 expression, a high level of
luciferase activity, due to the stathmin1 promoter, was detected
(Fig. 6E). Expression of Hes1 or Id3 in these cells inhibited
luciferase activity related to the stathmin1 promoter (Fig. 6E),
showing that Hes1 and Id3 blocked stathmin1 promoter activity
through endogenous Ascl1. In PC12 cells transfected with the
stathmin1 promoter plasmid and the Ascl1 expression plasmid,
luciferase activity was higher than that in PC12 cells without the
Ascl1 expression plasmid (Fig. 6F). Id3 expression in these cells
inhibited the up-regulation of stathmin1 promoter luciferase
activity, while Hes1 expression failed to reduce the luciferase
activity induced by exogenous Ascl1 (Fig. 6F). These findings
suggested that Id3 inhibits activation of the stathmin1 promoter by
both exogenous and endogenous Ascl1, while Hes1 only blocked
the effect of endogenous Ascl1. Thus, it is likely that Id3 regulates
Ascl1 at the protein level, while Hes1 regulates Ascl1 transcription.
If so, inhibition of Hes1 expression should increase the
transcription of Ascl1. As expected, up-regulation of Hes1 in
PC12 cells by PACAP stimulation led to inhibition of Ascl1
expression (Fig. 6G). And a reduction of Hes1 expression also
resulted in an elevation of Ascl1 expression to 1.2-fold the control
level (Fig. 6H, I). These results indicate that Ascl1, which controls
stathmin1 expression, was functionally regulated by Id3 and
quantitatively regulated by Hes1, in response to PACAP signaling.
Stathmin1 expression is increased in the brains of
patients with schizophrenia
Adcyap
2/2 mice are known to show behavioral abnormalities,
some of which might have potential relevance to mental disorders
such as schizophrenia [12]. The present study demonstrated that
PACAP inhibits stathmin1 expression both in vivo and in vitro.
Therefore, we examined whether stathmin1 mRNA levels were
altered in the brains of patients with schizophrenia. RT-PCR with
stathmin1 primers (after normalization with GAPDH and PGK1)
showed that the stathmin1 mRNA level was significantly increased
in schizophrenic patients compared with age-matched controls
(Fig. 7A). In contrast, stathmin1 was not significantly increased in
the brains of patients with bipolar disorder (Fig. 7B).
Discussion
We searched for genes that showed marked changes of
expression in the dentate gyrus of Adcyap
2/2 mice, because
PACAP may play a role in schizophrenia and the PAC1 receptor is
exclusively expressed in the dentate gyrus of the hippocampus. As
a result, we identified alterations in the expression of stathmin1.
This study provides the first in vivo and in vitro demonstration that:
(1) PACAP suppresses stathmin1 expression; (2) increased
expression of stathmin1 in SGZ neurons, due to PACAP
deficiency, causes abnormal axonal sprouting and stathmin1
over-expression in primary cultured hippocampal neurons induces
abnormal arborization; (3) ascl1 regulates stathmin1 expression; (4)
up-regulation of Id3 and Hes1 by PACAP stimulation inhibits
Ascl1; and (5) stathmin1 expression was increased in the brains of
patients with schizophrenia.
Increased stathmin1 expression in SGZ neurons due to
PACAP deficiency induces abnormal neurite outgrowth
There are no significant data about the morphological changes
of neurons in the hippocampus in postmortem brains of
schizophrenia patients. A tendency for dendrite lengths to be
shortened has been reported and the density of spines was reduced
in the cortex of schizophrenia patients [24]. What happens in the
brain after disturbance of the PACAP-PAC1-stathmin1 cascade?
To investigate this point, the functions of stathmin1 will need to be
explored, because, to date, little is known. It has been reported
that stathmin1 is required for the induction of long-term
potentiation (LTP) in afferent inputs to the amygdala and is
essential for regulating both innate and learned fear [25,26,27].
Cardinaux et al. reported that brain-derived neurotrophic factor
(BDNF) stimulates the phosphorylation of stathmin1 [28]. Row-
lands et al. showed that stathmin1 is expressed in proliferating cells,
but not in resting cells [29]. These findings suggest an important
role of stathmin1 in development, but the details of its actions in
the brain are still obscure. In the present study, stathmin1
expression was demonstrated in neurons of SGZ where neuro-
genesis is ongoing, even in adulthood. The SGZ contains neurons
in various stages of neurogenesis and a large number of SGZ
neurons expressed stathmin1, suggesting that it is expressed at a
specific stage of neurogenesis. Nestin is a marker of proliferating
neurons [30], but stathmin1 and nestin were localized in different
populations of neurons. PSA-NCAM and doublecortin (DCX) are
markers of migrating neurons [31,32], whereas NeuN is a marker
of mature neurons [33], and stathmin1 was co-localized with these
markers of neuronal differentiation (supplementary Fig. S2). These
results indicate that stathmin1 is not involved in the proliferation
of SGZ neurons, but influences their differentiation. Moreover, we
found stathmin1-expressing neurons in the rostral migratory
system, olfactory bulb, and piriform cortex (data not shown)
Figure 7. Expression of stathmin1 is increased in the brain of
schizophrenia patients. Comparison of mRNA levels of stathmin1 in
the postmortem brain of control subjects (open column) and schizo-
phrenia subjects (closed column) (A), or bipolar disorder subjects (B). The
relative expression levels of the gene, normalized to GAPDH or PGK1, are
presented. The expression of stathmin1 normalized to GAPDH (Mann-
Whitney test, p=0.0082) and PGK1 (Mann-Whitney test, p=0.0047) were
significantly increased in the schizophrenia group, compared with the
control group.
doi:10.1371/journal.pone.0008596.g007
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during adulthood. Furthermore, PAC1 was co-localized with
stathmin1 in the olfactory bulb and piriform cortex (data not
shown). These findings suggest that PACAP signaling regulates
stathmin1 expression and controls neurogenesis.
Furthermore, we explored the role of stathmin1 in neurite
outgrowth, because over-expression of stathmin1 by hippocampal
neurons caused pronounced aberrant arborization of axons both in
vivo and in vitro. Stathmin1 knock-out mice show normal neuronal
morphology [25], while over-expression of stathmin1 after
reduction of PACAP signal induces abnormal arborization of
axons. These findings suggested that stathmin1-related proteins,
such as SCG10 [34], can compensate for the lack of stathmin1
activity in developing cells, but destabilization of microtubules
(MTs) by an increase of stathmin1 is unavoidable because it
interacts directly with tubulin [35,36]. It can be suggested that the
regulation of MT stability in the early stage of neurogenesis is
important for the correct formation of neurons. Although we
detected increased in vivo arborization of axons in the polymorphic
layer, no obvious morphological changes of the dendrites were
observed. Further investigation is needed to elucidate why
stathmin1 expression causes the sprouting of axon fibers only.
Previously, Inokuchi et al. reported the curious finding that both
over-expression and down-regulation of stathmin1 inhibited the
outgrowth of dendrites from cultured Purkinje cells [35,37].
However, even they found no morphological alterations of the
dendrites of Purkinje cells in stathmin1 knock-out mice, and
explained this as being due to the compensatory effect of
stathmin1-related molecules [38]. Although it is difficult to explain
the discrepancy between the present and previous findings, it
could be attributable to differences among the neurons studied.
Taken together, the data suggest that regulation of proteins related
to MT stability regulates axon or dendrite formation and that
these proteins are modulated by neurotrophic factors, such as
PACAP.
Molecular mechanism for PACAP inhibition of stathmin1
expression in SGZ neurons
It was previously shown that the expression of stathmin1 in
PC-3-M cells is predominantly mediated through the E2F family
of transcription factors [39]. From BLAST search, it indicates
that the stathmin1 promoter region contains multiple bHLH
binding sites. In addition, human and mouse stathmin1
promoters have several E boxes, and these transcriptional sites
should be key motifs for regulating stathmin1 expression. As
mentioned above, stathmin1 was co-localized with DCX and
PSA-NCAM in the SGZ. Neuronal transcription factors from the
family, such as Ascl1 and NeuroD, are expressed before the
migration stage, which is when expression of DCX or PSA-
NCAM occurs [40]. We examined the effect of Ascl1 and
NeuroD on the stathmin1 promoter by using a luciferase assay.
Ascl1 was shown to enhance luciferase activity related to the
stathmin1 promoter, but NeuroD did not (data not shown). Ascl1
and all the members of the bHLH family heterodimerize through
their HLH domain with ubiquitously expressed bHLH E
proteins, such as E2A gene products (E12 and E47). Heterodi-
mers bind to DNA through their basic domain and activate the
transcription of genes that have an E box in the promoter region
[41]. Thus, it can be suggested that heterodimers of Ascl1 and
E 4 7b i n dt ot h eE 1 0b o xm o t i fo ft h es t a t h m i n 1p r o m o t e rr e g i o n
and activate stathmin1 expression.
The present study suggested the molecular cascade by which
PACAP inhibits stathmin1 expression (Fig. 2, 5 and 6). Neuronal
differentiation is known to be not only regulated by transcriptional
bHLH activators, but also by inhibitory bHLH proteins, such as
the Hes and Id family of repressors. We found that Hes1 and Id3
were rapidly up-regulated by PACAP, and activation of Ascl1 was
inhibited by both Hes1 and Id3. Hes1 expression was increased via
both the PACAP-PAC1-ERK and PACAP-PAC1-p38 pathways,
whereas Id3 was up-regulated via the PACAP-PAC1-p38 pathway
only. We also detected different mechanisms for the inhibition of
Ascl1 by Hes1 and Id3. First, Hes1 regulates the transcription of
Ascl1. We observed that Hes1 was up-regulated by PACAP, but
Hes5 was unchanged (data not shown). The Hes family can inhibit
gene expression either by directly binding (as homodimers) to
cognate-binding elements known as N-boxes (CACNAG) or
indirectly by dominant-negative regulation (i.e., forming non-
functional heterodimers with transcriptional activators) [41]. It has
been shown that the repressive effect of Hes1 is directly mediated
by its binding to a class C site in the hAsh1 promoter [42]. Hes1 is
thought to regulate the onset of neuronal differentiation, at least
partly, by repressing the transcription of downstream positive
factors, such as the neuronal commitment gene, Ascl1. Therefore,
Hes1 (which was up-regulated by PACAP) binds the Ascl1
promoter and inhibits Ascl1 expression. On the other hand, Id3
regulates the function of Ascl1 protein. Id proteins have been
identified as negative regulators of bHLH transcription factors and
Id1 through Id4 have been characterized in mammals. It was
previously shown that Id3 is a cAMP-responsive gene, the up-
regulation of which could be involved in PACAP signaling [43].
We observed that Id3 was up-regulated by PACAP stimulation,
but Id1, Id2 and Id4 increased at a later phase (data not shown).
These transcriptional regulators inhibit bHLH factors by seques-
tering them in inactive heterodimers, which are unable to bind
with DNA due to the absence of a basic DNA-binding region in
the Id proteins. In addition, previous findings have indicated that
Id1 and E protein levels not only regulate the transcription but also
the stability of Ascl1 [44]. Thus, our results suggest that Id3 binds
E protein and suppresses Ascl1.
The present study indicated that PACAP signaling increased the
levels of Hes1 and Id3, following these inhibitory bHLH proteins
decreased the expression of stathmin1 (supplementary Fig. S3).
Increased stathmin1 expression in SGZ neurons due to
PACAP deficiency and psychiatric illness
PACAP and PAC1 knock-out mice show abnormal behavior
resembling psychiatric disorders [5] and some SNPs in the vicinity
of the PACAP gene locus are associated with schizophrenia. These
findings suggested that the brains of schizophrenic patients may be
deficient in PACAP and PAC1, resulting in increased expression of
stathmin1 in the SGZ neurons of the dentate gyrus. In addition,
up-regulation of stathmin1 has previously been implicated in
schizophrenia pathogenesis from the results of scanning and from
comparing the anterior cingulate cortex gray matter proteomes
between schizophrenia and control post-mortem human tissue
using two-dimensional gel electrophoresis [45]. As expected, the
present study revealed an increase in the expression of stathmin1
mRNA in the brains of schizophrenic patients, but not in the
brains of patients with bipolar disorder. The fold-index indicated
about 1.5 (schizophrenia/control), which corresponded well to the
level (1.8) in the report above. However, no SNPs displayed any
allelic, genotypic, or haplotypic associations with schizophrenia
(supplementary Table S1).
Recent studies have provided reliable evidence that schizophre-
nia is a neurodevelopmental disease [46,47,48]. The present study
revealed that PACAP deficiency causes increased stathmin1
expression in SGZ neurons and leads to abnormal sprouting of
their axons, showing that PACAP deficiency and consequently
Stathmin1 Causes Abnormal Axon
PLoS ONE | www.plosone.org 11 January 2010 | Volume 5 | Issue 1 | e8596over-expression of stathmin1 in SGZ neurons could lead to a
disturbance of the neural circuits in the dentate gyrus. This raises
the possibility that abnormal expression of PACAP and stathmin1
could interfere with dentate gyrus functions, leading to an
increased susceptibility to psychiatric illnesses.
Supporting Information
Figure S1 P38 or ERK activation in PC12 cells in response to
PACAP stimulation. PC12 cells were treated with 100 nM
PACAP. After the stimulation, cells were lysed at each indicated
times. Upper 2 panels: Activations of p38 were detected by
immunoblotting analysis using the phosphospecific anti-p38
antibody. To control for loading, Western blotting analyses of
lysates were performed with anti-p38 antibody. Lower 2 panels:
Activations of ERK were also detected by immunoblotting analysis
using the phosphospecific anti-ERK antibody. To control for
loading, Western blotting analyses of lysates were performed with
anti-ERK antibody. Used antibodies as follows; anti-P38 antibody
(Cell Signaling. rabbit polyclonal, 1:1000 dilution), anti-phoso-
pholylated P38 antibody (Cell Signaling. rabbit polyclonal, 1:1000
dilution), anti-ERK antibody (Cell Signaling. rabbit polyclonal,
1:1000 dilution), anti-phosopholylated ERK antibody (Cell
Signaling. rabbit polyclonal, 1:1000 dilution). Note: Both
P38 and ERK were activated at 5–10 minutes after PACAP
stimulation.
Found at: doi:10.1371/journal.pone.0008596.s001 (0.40 MB TIF)
Figure S2 Localisationofstathmin1withmarkersofvariousstages
in neurogenesis in dentate gyrus of 8 week-mice. A–C. Mouse
hippocampus (dentate gyrus) was stained with anti-stathmin1 and
anti-nestinantibodies (A, stathmin1:green, B,nestin: red, C,merged
image). D–G. With anti-stathmin1 and anti-PSA-NCAM antibodies
(D,E, stathmin1: green, D,F, PSA-NCAM: red, D,G, merged
image). E–G: Higher magnification of D. scale bar=50mm. H–K.
With anti-stathmin1 and anti-doublecortin (DCX) antibodies (H,I,
stathmin1:green, H,J,DCX: red, H,K, merged image). I–K: Higher
magnification of H. scale bar=50mm. L. Merged image with anti-
stathmin1 and anti-NeuN antibodies (stathmin1: green, NeuN: red)
scale bar=50mm. Mice under deep pentobarbital anesthesia were
perfused transcardially with 30–50 ml of 4% paraformaldehyde
solution.Brainwasremovedandinfusedwith30%sucroseovernight
at 4oC. After blocking with 5% bovine serum albumin, each sections
were incubated overnight at 4 oC with an anti-stathmin1 antibody
(GeneTex, Inc. rabbit-polyclonal, 1:1000 dilution) and either anti-
nestin (Becton Dickinson. Mouse-monoclonal, 1:1000 dilution), anti-
PSA-NCAM (abcys. Mouse-polyclonal, 1:1000 dilution), anti-
doublecortin (DCX) (Santa Cruz Bio. Goat-polyclonal, 1:1000) or
anti-NeuN (Chemicon. mouse-monoclonal, 1:1000 dilution) anti-
body in 0.01 M PBS containing 0.3% Triton X-100 and 5% BSA.
Next, the sections were treated with fluorescent dye (Alexa Fluor
488)-conjugated donkey anti-rabbit IgG (1:1000 dilution), fluores-
cent dye (Alexa Fluor 568)-conjugated goat anti-mouse IgG (1:1000
dilution), and donkey anti-goat IgG (1:1000) as the secondary
antibodies for 1 h at RT in 0.01 M PBS containing 5% BSA. Each
sections were observed under a confocal microscope (LSM510, Carl
Zeiss).
Found at: doi:10.1371/journal.pone.0008596.s002 (1.76 MB TIF)
Figure S3 Schematic drawing of the molecular pathway of
PACAP regulation on stathmin1 expression shown in this study. A
schematic representation of the pathway which PACAP regulates
expression of stathmin1 by suppressing the function and
expression of Ascl1 after increasing the expression of Hes1 and
Id3 by activating ERK and p38.
Found at: doi:10.1371/journal.pone.0008596.s003 (2.51 MB TIF)
Table S1 Single SNP transmission disequilibrium test (TDT)
results of stathmin1 SNPs
Found at: doi:10.1371/journal.pone.0008596.s004 (0.37 MB TIF)
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